Home › Funds › Vivo Capital, LLC › TRVI

Vivo Capital, LLC position in TRVI

TREVI THERAPEUTICS INC · Health Care

Vivo Capital, LLC reported holding 4,229,683 shares of TRVI (TREVI THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$60.6M, representing 6.88% of its reported portfolio and ranking #2 among its reported holdings. Vivo Capital, LLC has disclosed TRVI holdings in 9 of the last 9 reported quarters, going back to Q3 2024.

Latest position (Q3 2026)4.23M sh
Reported value held$60.57M
Portfolio Weight6.88%
First reportedQ3 2024
Last changeReduce
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How Vivo Capital, LLC's TRVI position evolved

Vivo Capital, LLC first disclosed a stake in TRVI in Q3 2024 at 1,612,903 shares (US$5.4M). The position peaked in Q2 2026 at 5,094,668 shares, worth US$95.0M. Across 9 filings, Vivo Capital, LLC increased the stake 3 time(s), trimmed it 1 time(s) and left it unchanged 4 time(s). The most recent filing (Q3 2026) shows 4,229,683 shares valued at US$60.6M — a reduction of -864,985 shares quarter over quarter.. Notable position changes include a 116% increase in Q4 2024 (shares rose 53% over the following quarter), a 29% increase in Q2 2025 (shares rose 67% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2024 1.61M $5.39M New
Q4 2024 3.49M $14.37M Add
Q1 2025 3.49M $21.94M Hold
Q2 2025 4.49M $24.55M Add
Q3 2025 5.09M $46.62M Add
Q4 2025 5.09M $63.79M Hold
Q1 2026 5.09M $60.78M Hold
Q2 2026 5.09M $95.02M Hold
Q3 2026 4.23M $60.57M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About TRVI and 13F data

TRVI (TREVI THERAPEUTICS INC) is a Health Care company. 61 other funds we track also report a position in TRVI — the largest reported positions include NEA Management Company, LLC (US$246.6M), Frazier Life Sciences Management, L.P. (US$185.4M), Vestal Point Capital, LP (US$57.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding TRVI

All TRVI fund holders →

FAQ

How long has Vivo Capital, LLC held TRVI?

Vivo Capital, LLC has disclosed TRVI holdings in 9 of the last 9 reported quarters, going back to Q3 2024.

What is Vivo Capital, LLC's current position in TRVI?

As of Q3 2026, Vivo Capital, LLC holds 4.23M shares of TRVI (TREVI THERAPEUTICS INC), valued at $60.57M, representing 6.88% of its reported portfolio and ranking #2.

Has Vivo Capital, LLC been buying or selling TRVI?

In the latest 13F filing (Q3 2026), Vivo Capital, LLC reduced its position in TRVI. The position peaked in Q2 2026 at 5.09M shares.

Which other funds hold TRVI?

Other major institutional holders of TRVI include NEA Management Company, LLC, Frazier Life Sciences Management, L.P., Vestal Point Capital, LP, among 61 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.